Alternated delta and mu receptor activation: a stratagem for limiting opioid tolerance.
The development of tolerance to the antinociceptive effects of chronically administered delta (delta) and mu (mu) agonists was examined in vivo in rats using a protocol of alternated preferential activations of delta and mu receptors. This was accomplished by alternated chronic administrations of the relatively delta- and mu-selective agonists DADLE ([D-Ala2, D-Leu5]-enkephalin) and morphine sulfate (MSO4), respectively. Specifically, the agonists were given as 3 sequential 6 day cycles: (1) osmotic pump infusions of DADLE into the lumbar intrathecal space; (2) followed by intraperitoneal injections of MSO4; (3) followed again by intrathecal DADLE infusions. Following each cycle, the agonists' antinociceptive activities were measured using the tail-flick test of nociception. These were compared to their baseline (i.e., drug-naive) activities as a measure of tolerances. In a separate experiment the same total intrathecal dose of DADLE was infused chronically over twelve days without an interposed dose of MSO4. In the alternated agonist experiment, DADLE's antinociceptive ED50 value was increased by 10.4-fold, then reverted to only a 1.5-fold change from baseline and was subsequently shifted to a 13.7-fold increase over baseline. After cycle 2 with MSO4 a significant recovery from DADLE tolerance was noted as compared to that following cycle 1: 1.5- versus 10.4-fold, respectively. Furthermore, the interposition of a cycle of MSO4 between two cycles of DADLE resulted in a much lesser degree of tolerance for DADLE following cycle 3 (12 days of non-continuous DADLE infusion) than was noted after the 12 day continuous DADLE intrathecal infusion (13.7- versus 25.0-fold tolerance, respectively).(ABSTRACT TRUNCATED AT 250 WORDS)
Russell
Roy Dallas
RD
(R.D.R., K.-J.C.) Department of Anesthesiology, Duke University Medical Center, Durham, NC 27710 U.S.A. (K.-J.C.) Department of Molecular Biology, Burroughs Wellcome Company, RTP, NC 27709 U.S.A.
Kwen-Jen
Chang
C
D000818:Animals; D004305:Dose-Response Relationship, Drug; D004333:Drug Administration Routes; D004361:Drug Tolerance; D004743:Enkephalin, Leucine / Q000008:administration & dosage / Q000031:analogs & derivatives*; D016308:Enkephalin, Leucine-2-Alanine; D007260:Infusion Pumps; D007274:Injections, Intraperitoneal; D009020:Morphine / Q000008:administration & dosage*; D009270:Naloxone / Q000494:pharmacology; D010147:Pain Measurement; D051381:Rats; D011919:Rats, Inbred Strains; D011957:Receptors, Opioid / Q000187:drug effects*; D017465:Receptors, Opioid, delta; D017450:Receptors, Opioid, mu; D013997:Time Factors
D011957:Receptors, Opioid; D017465:Receptors, Opioid, delta; D017450:Receptors, Opioid, mu; D009270:Naloxone; D004743:Enkephalin, Leucine; D016308:Enkephalin, Leucine-2-Alanine; D009020:Morphine